Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 17 May 2002:
Vol. 296. no. 5571, p. 1212
DOI: 10.1126/science.296.5571.1212
Prev | Table of Contents | Next

News of the Week

INTELLECTUAL PROPERTY:
DuPont Ups Ante on Use of Harvard's OncoMouse

Eliot Marshall

DuPont is becoming more assertive about asking U.S. researchers to obtain licenses for permission to use the Harvard OncoMouse. The company--arguing that its OncoMouse patents cover any transgenic animal predisposed to cancer--is also asking institutions to enforce the agreements. Some have complied readily, according to DuPont, but others, including the Massachusetts Institute of Technology and the University of California, appear to be dragging their feet. And a few researchers and administrators are up in arms.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer.
D. Hanahan, E. F. Wagner, and R. D. Palmiter (2007)
Genes & Dev. 21, 2258-2270
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)